Telmisartan Market To Surpass US$ 4.3 Billion By 2026 - Coherent Market Insights
Telmisartan Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
Telmisartan is a prescription medication often prescribed to relax and widen blood vessels in persons with high blood pressure. Telmisartan belongs to a group of drugs called angiotensin II receptor blockers (ARBs). Telmisartan may be used alone or in combination with other medications such as hydrochlorothiazide for treatment of high blood pressure. Increasing awareness regarding hypertension and its management by organizing global campaigns are expected to drive growth of the market.
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/
Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on "Global Telmisartan Market" by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke), by Composition (Single and Combinational)
Key players are focused on development and launch of new generic product to maximize access to end users for their product in less cost, in turn gaining market share in telmisartan market. For instance, in June 2017, Solco Healthcare, announced its FDA approval for Telmisartan tablets, 20mg, 40mg, and 80mg, which are AB-rated equivalents to Micardis by Boehringer Ingelheim. Solco Healthcare will market Telmisartan tablets in 30 count bottles for all three strengths.
Browse Research Report: https://www.coherentmarketinsights.com/
Key Takeaways of the Telmisartan Market:
The global telmisartan market is expected to expand at a CAGR of 1.4% during the forecast period (2018 – 2026), owing to continuous marketing approvals for telmisartan.
Among strength, 80 mg segment is expected to hold leading position in the global telmisartan market, owing to approval from USFDA of telmisartan 80 mg in combination with other drugs.
Major players operating in the global telmisartan market include C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.
Buy-Now this research report: https://www.coherentmarketinsights.com/